Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PTCT ; NEW IPO.. Offered @ $15; Closed @ $13.63
PTC Therapeutics Closes Initial Public Offering
PR NewswirePress Release: PTC Therapeutics, Inc. – Tue, Jun 25, 2013 11:52 AM EDT
RELATED QUOTES
Symbol Price Change
PTCT 13.63 -2.41
SOUTH PLAINFIELD, N.J., June 25, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) (PTCT) today announced the closing of its initial public offering of 9,627,800 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts, including 1,255,800 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )
J.P. Morgan and Credit Suisse acted as joint book-running managers for the offering. Cowen and Company acted as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013. Copies of the final prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.
Blue;
Good data!
Short squeeze will be underway again and again.
GLLs
Blue;
Yes indeed!
GLLs
Today's senate bill
"Although the bill has bipartisan support, the road to passage may be long and bumpy, analysts said.
“With housing stabilizing and the GSEs profitable, Congress could also choose to focus on fiscal policy or other topics near term,” Barclays analysts recently wrote about the bill’s draft version.
Indeed, Fannie and Freddie have been reporting improving financial results, thanks to a rebounding housing market. With their strengthening reports, the government sponsored enterprises have been sending dividends to Treasury, and have so far sent a total of more than $130 billion. The two firms received a total of almost $190 billion in government support, but the dividends sent to Treasury do not pay down that amount.
There’s some concern that U.S. lawmakers are “addicted” to these payments from Fannie and Freddie, as they are helping to narrow the deficit."
–Ruth Mantell
http://blogs.marketwatch.com/capitolreport/2013/06/25/housing-finance-overhaul-bill-introduced-in-senate/?mg=blogs-wsj
Good sign!
So did I! Good idea.
Adding! Good opportunity!
GLLs!
yep!
Blue;
Good timely post!
Afxm; Good one!
GLLs.
mlkrborn
application for FDA approval of VBLOC therapy in obesity $1.16
Seattle Genetics enters into new antibody-drug conjugate collaboration with Bayer (BAYRY) (SGEN) 29.90 : Co announced that it has entered into a new antibody-drug conjugate collaboration with Bayer HealthCare (BAYRY). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 mln for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics is also eligible to receive up to ~$500 mln in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products under the collaboration.
Vical and Astellas (ALPMY) announce initiation of Phase 3 trial of ASP0113 cytomegalovirus vaccine (VICL) 3.01 : Vical and Astellas Pharma (ALPMY) announced the initiation of a multinational Phase 3 registration trial of ASP0113 (TransVax), in ~ 500 hematopoietic cell transplant (HCT) recipients. Vical and Astellas entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113, Vical's investigational therapeutic vaccine designed to control cytomegalovirus (CMV) in transplant recipients. Astellas is conducting the trial, and Vical is providing development, regulatory and manufacturing support. The cos expect to begin a separate Phase 2 trial of ASP0113 in solid organ transplant recipients later this year.
ADEEZI; Is it Adeezi's barometer to decide when to get in? Point us the right stage. Noticed you in FNMA too.. where else?
tia
GL
mlkr
Interesting one!
GL
mlkr
Blue;
Good observation. Will zip tru $2.00 level it seems..
Your posts help!
Marked you!
GLLs
GenMark Diagnostics sees FY13 revenues of approx $30 mln compared to prior guidance of $35 mln (GNMK) 10.97 -1.00 : As a result of additional uncertainties relating to the future revenue contribution from its largest customer, together with persisting reimbursement and other challenges affecting the emerging pharmacogenomics market sector, the Company is updating its annual revenue guidance to approximately $30 million from its original estimate of approximately $35 million.
"In light of the recent developments which introduced additional uncertainty regarding this customer, we have taken a more conservative outlook and reduced our revenue expectations for the remainder of the year," Massarany further stated. "Nevertheless, we believe the significant growth rates we are experiencing in our core business strengthen our position and support year-over-year growth of about 50%, resulting in approximately $30 million of annual revenue. Furthermore, we continue to make excellent progress toward the development of our NexGen sample-to-answer system, which we believe will fuel significant growth and our future success as a global leader in molecular diagnostics."
GERN 1.15 Geron reports updated results from its Imetelstat Phase 2 proof-of-concept trial in Essential Thrombocythemia (GERN) 1.14 : Co announces that updated clinical results from the co's Phase 2 trial of imetelstat in essential thrombocytopenia were presented in an oral session at the Congress of the European Hematology Association.
Efficacy Results
All 18 ET patients were refractory to, intolerant of or had refused conventional therapies (hydroxyurea, anagrelide and/or interferon-alpha). Platelet counts were reduced in all patients (a 100% hematologic response rate) and normalized in 16 out of 18 patients (an 89% complete response (CR) rate). The JAK2 V617F gene mutation was detected in eight patients. Seven out of the eight (88%) patients achieved 72% to 96% reductions in JAK2 V617F allele burden that qualified as partial molecular responses within three to 12 months of treatment with imetelstat. Molecular PRs were maintained in six of the seven (86%) patients, with a median follow-up of 9.5 months (range 0 to 19 months) after first achieving a response. The median durations of hematologic and molecular response have not yet been reached.
Safety Results
In the trial, long-term administration of imetelstat was generally well tolerated. There were no new safety signals observed in the six-month update, and no patients discontinued the trial due to drug-related adverse events. The majority of the non-hematologic adverse events were mild-to-moderate in severity, the most frequent assessed as imetelstat-related by investigators being gastrointestinal events and fatigue. No drug-related Grade 4 non- hematologic adverse events were reported.
Intercept Pharma announced that it has commenced an underwritten public offering of 1.73 mln shares of its common stock (ICPT) 32.51 : BofA Merrill Lynch and Citigroup are acting as joint book-running managers, BMO Capital Markets is acting as lead manager and Needham & Company, Wedbush PacGrow Life Sciences and Janney Montgomery Scott are acting as co-managers for the proposed offering. Co intends to use substantially all of the net proceeds of this offering to fund the development of its lead product candidate, obeticholic acid (OCA), for additional indications beyond primary biliary cirrhosis (PBC); the continuation of the long-term safety extension portion of its POISE trial and a proposed Phase 3 clinical outcomes trial after the anticipated filings with the FDA and European Medicines Agency; certain pre-commercialization and potential commercial launch activities of OCA for PBC; and general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of its intellectual property.
Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly (LLY) (TTHI) 3.51 : Co announces it has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a $7 mln milestone payment.
Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of $14 mln to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately $240 mln in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds.
Biodel announces data presentations at American Diabetes Association Annual Meeting; presented demonstrate significant progress in the development of both recombinant human insulin-based and insulin analog-based formulations with ultra-rapid-acting profiles (BIOD) 4.22 : Co will present data from human and animal studies with its ultra-rapid-acting prandial insulin product candidates during the 73rd Scientific Sessions of the American Diabetes Association being held from June 21 to June 25. The data to be presented demonstrate significant progress in the development of both recombinant human insulin-based and insulin analog-based formulations with ultra-rapid-acting profiles. "We will present clinical data on BIOD-238 and BIOD-250, which demonstrate significantly more "rapid in" and "rapid out" pharmacokinetic profiles relative to Humalog and could address an unmet medical need for prandial insulins with profiles more closely resembling normal physiology. Dr. Pohl will present the evaluation of concentrated insulin candidate BIOD-531 in the diabetic swine model, which showed an early absorption profile similar to or superior to that of Humalog and superior to Humulin R U-500. BIOD-531has been selected for Phase 1 clinical study as it could address an unmet medical need for the growing population of severely insulin resistant type 2 diabetes patients who require greater than 200 units of insulin daily and for whom no rapid-acting or ultra-rapid-acting concentrated insulins currently exist."
Bioscrip to acquire CarePoint Partners Home Infusion business for $223 mln (BIOS) : Co announces that it has entered into a definitive agreement to acquire the business of CarePoint Partners Holdings and its subsidiaries for $223 million in cash, subject to certain adjustments. CarePoint Partners is a national provider of home and alternate-site infusion therapy for patients with complex, acute and chronic illnesses. BioScrip also expects to realize the value of a future tax benefit estimated at $45 million as a result of the transaction, yielding a net purchase price of $178 million.
Headquartered in Cincinnati, Ohio, CarePoint Partners is expected to generate approximately $160 million in annual revenue, services approximately 20,500 patients annually, and has 28 sites of service in nine states within the East Coast and Gulf Coast regions. With the addition of CarePoint Partners, BioScrip will provide home infusion services to approximately 100,000 patients.
CarePoint Partners is expected to generate approximately $160 million in annual revenue. Once fully integrated, this business should generate Adjusted EBITDA margins between 12% and 14%. BioScrip estimates that an acquisition of this size can take 12 to 15 months to fully integrate.
GLCH 13.97! Regains listing.
RELATED QUOTES
Symbol Price Change
GLCH 13.97 -0.07
NEW YORK--(BUSINESS WIRE)--
Gleacher & Company, Inc. (GLCH) announced that it has been notified by The NASDAQ Stock Market LLC (“NASDAQ”) that it has regained compliance with the minimum bid price requirement under the NASDAQ listing standards. NASDAQ also confirmed that the Company is in compliance with all other applicable requirements for listing on The NASDAQ Global Market.
Rosetta Genomics: Medicare Administrator issues final local coverage determination for Rosetta cancer origin test (ROSG) 3.95 +0.13 : Co announces that Novitas Solutions, the designated Medicare Administrative Contractor (MAC) for the Company's microRNA-based diagnostic assays, has issued for notice the final revised Local Coverage Determination (LCD) for Biomarkers in Oncology, which includes the Rosetta Cancer Origin Test, the Rosetta Lung Cancer Test and the Rosetta Kidney Cancer Test (formerly miRview mets2, lung and kidney assays). The LCD will become effective as of August 1, 2013. The final revised LCD confirms continued Medicare coverage for the Cancer Origin Test to identify Cancer of Unknown or Uncertain Primary (CUP) as originally reported in Novitas' bulletin posted in June 2012, and for which they have been reimbursing the test at approximately $3,500 per test. This final policy determination was based on peer-reviewed publications from clinical studies conducted internally at Rosetta Genomics and at world-renowned institutions that demonstrated the test's clinical utility.
Cempra provides guidance on the clinical program required for regulatory approval for solithromycin for community-acquired bacterial pneumonia (CABP) (CEMP) 8.13 +0.18 :
"We believe our End-of-Phase 2 meeting with the FDA has provided us with clear direction toward approval of solithromycin for CABP," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. "We were pleased with the FDA input and believe we are in a position to proceed with our second Phase 3 study and the rest of the clinical program, subject to receipt of the necessary funding. We know the requirements for the CABP safety database and efficacy endpoints for NDA submission. In addition, we received preliminary feedback on the trial design for the uncomplicated gonococcal infection indication."
The Phase 3 solithromycin clinical program in CABP will be planned to consist of an oral trial and an intravenous (IV)-to-oral clinical trial. Cempra followed the CABP guidance that the FDA proposed in a November, 2011, meeting of the Anti-Infective Drugs Advisory Committee. The FDA provided comments on the Phase 3 oral CABP protocol in June, 2012, and this global study is ongoing. This study compares five days of oral solithromycin with seven days of oral moxifloxacin. FDA responses prior to and at the End-of-Phase 2 meeting addressed the second Phase 3 study, which is the planned intravenous-to-oral step-down trial.
So much BS!
This must be the reason for temporary pull bak: BKIR 0.16s in europe today: GSUX downgrade:
http://www.businesspost.ie/#!story/Home/News/Bank+of+Ireland+falls+after+Goldman+cuts+rating/id/19410615-5218-51b6-011a-e11169383605
Bank of Ireland continues to face operating headwinds, Goldman analysts said.
Bank of Ireland fell the most in more than two months in Dublin trading after Goldman Sachs Group cut its rating on the company’s stock to sell from neutral.
Bank of Ireland fell as much as 5 per cent to 17 cents in Dublin, the biggest intra-day decline since March 27th. Trading volume in the stock was 46 per cent of the average for the past three months at about 44.4 million shares.
In a note published today, Goldman Sachs said that the bank’s discount compared to European peers has closed this year and is now trading at 1 times estimated tangible book value, up from 0.6 times at the start of 2013.
“Despite better prospects for the Irish economy and progress on restructuring, the bank continues to face operating headwinds,” Goldman analysts said, adding it expects the bank only to reach break-even next year.
(reporting from Bloomberg)
.....
InVivo Therapeutics raises $16.1 mln from warrant call and exercises paving way for up-listing to a national securities exchange (NVIV) 3.62 : Co announced that the call notice period for the early exercise of warrants issued to investors on Oct 26, 2010, Nov 10, 2010 and Dec 3, 2010 expired on June 3, 2013. By the expiration of the call period, 100% of the Investor Warrants were exercised. The exercises during the call period, coupled with warrant exercises during April 2013, raised $16.1 mln gross and $15.6 mln after solicitation expenses. ~ 11.5 mln shares of common stock were issued in connection with these warrant exercises. The combination of the exercise of all the Investor Warrants along with the warrant exchange offer completed on May 17, 2013 for placement agent and other eligible warrants resulted in the complete reversal and elimination of the $24.6 mln warrant liability recorded on InVivo's books as of March 31, 2013. As of June 3, 2013, the co had cash on hand of $23.6 mln and total stockholders' equity of $23.7 mln, which exceeds the minimum stockholder's equity requirements for national securities exchanges.
Interesting move!
Novavax makes public tender offer to acquire all outstanding shares and warrants of Sweden-based Isconova AB; total transaction valued at ~ $29.6 mln (NVAX) 1.89 : Co announced that it has made a public tender offer to acquire all outstanding shares and warrants of Sweden-based Isconova AB directly from such holders and intends to make a private offer for all outstanding stock options. The total transaction is valued at ~ $29.6 mln based on the June 3, 2013 closing stock price of Novavax's common stock. The offer has been recommended by Isconova AB's board of directors in a press release that was issued earlier this morning. Novavax will acquire all outstanding Isconova AB shares for ~ 15.5 million shares of Novavax common stock, corresponding to an offer value of SEK 15.46 for each Isconova share. In addition, Novavax has offered to cash out all outstanding 2005-I warrants and 2005-II warrants for SEK 140,277, based on a "Black-Scholes" valuation. Pursuant to the private offer for stock options, Novavax intends to issue 218,120 shares of Novavax common stock, corresponding to a value of SEK 8.30 for each option share.
Looking reversed..Call options positive as well ..$ higher 2.0s
RELATED QUOTES
Symbol Price Change
CHTP 2.11 0.18
Chelsea Therapeutics does not typically see much option activity, but traders are turning bullish on the name.
The pharmaceutical company averages just 218 contracts per session, but yesterday it saw 1,600 July 2 calls change hands. Three prints of 500 each were purchased for $0.19 in volume far above the strike's previous open interest of just 65 contracts, clearly indicating that this is fresh buying.
These long calls are betting that CHTP will rally above $2.19 by mid-July. The options lock in the price where the stock can be bought no matter how far it might rise, but they could expire worthless if the shares don't move. (See our Education section)
CHTP ended yesterday's session flat at $1.84. The stock reached a 52-week high of $2.17 on March 27 but has been trading in an increasingly tight range since then. The company, which reported first-quarter results on May 1, is seeking approval from the Food and Drug Administration for a neurological drug proposed to treat Parkinson's disease and other disorders.
The July 2 calls made up almost all of the name's total volume of 1,787 contracts yesterday. Only 41 puts changed hands, further reflection of the session's bullish sentiment.
Get even with short pricks!
Very important development!
Thnx.
Greener;
Hang in .
It is not that bad average cost. That happens.
You will be OK!
GLLs.
Shylo;
good point!
National Bank of Greece SA (NBG) Active Despite Reverse Split: $7.11
May 30, 2013 10:17 AM EDT Send to a Friend
Get Alerts NBG Hot Sheet
Price: $7.10 -97.28%
Overall Analyst Rating:
NEUTRAL ( Up)
Trade NBG Now!
National Bank of Greece SA (NYSE: NBG) is seeing action Thursday following the bank's 1-for-10 reverse split. Despite the reverse split, volume is running ahead of normal.
Gleacher announces 1-for-20 reverse stock split: $0.70
Investment bank Gleacher & Co. announces 1-for-20 reverse stock split
Associated PressAssociated Press – 11 mins ago
NEW YORK (AP) -- Investment bank Gleacher & Co. has announced a 1-for-20 reverse stock split as it continues pondering a potential sale of the company. The news comes less than a week after Gleacher disclosed that it fired its CEO and chief operating officer.
A reverse stock split reduces the number of shares in circulation. Gleacher' move will give stockholders 1 share for every 20 shares they own.
The company did not say why it was performing the reverse stock split. It did say that the move was approved by its shareholders a week ago during its annual stockholders meeting. The board was authorized to implement the reverse stock split and to determine the ratio of the split, within a range of not less than 1-for-10 but not more than 1-for-20.
The reverse stock split is effective after the market close on Thursday. Shares will start trading on a split-adjusted basis on Friday. It will continue to list on the Nasdaq Global Market under the "GLCH" ticker symbol.
The reverse stock split comes days after Gleacher announced the firing of CEO Thomas Hughes and COO John Griff in a regulatory filing. That follows an April announcement by Gleacher that it might eliminate up to about 160 jobs. And in March the New York company disclosed that its finances had worsened and that it was again considering a sale of the company. It has already exited its fixed-income business, and it agreed to jettison most of its ClearPoint home mortgage business for an undisclosed amount in February.
Gleacher's stock shed about 1 cent to 69 cents in Thursday afternoon trading.
They must had settled another 100k shares trade @ $3.15 at @ 6.09 pm. Strange.
yes indeed!
GL
1,394, 000 shares bought at ask, $3.5965 while offers quoted @ $2.91. Unusual one indeed.